COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Watch the WCG COVID-19 Webinar Series On-Demand
Join thousands of your peers in watching WCG’s webinar series, where clinical trial and public health experts provide the insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from June 11, 2021
Recent Insights from WCG
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
CanSino Biologics’ COVID-19 Vaccine Gets EUL From the WHO
The WHO is recommending the vaccine for people age 18 years and older.
FDA OKs Booster of Pfizer-BioNTech COVID-19 Vaccine for Kids Five to 11
The FDA has authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for children age five through 11 years.
FDA Provides Update on Woodside Acquisitions’ Recall of Its COVID-19 Tests
The FDA said it has received no reports of injuries, deaths, or adverse events associated with the recalled tests.
AstraZeneca Gains Rights to RQ Biotechnology’s COVID-19 Monoclonal Antibodies
“The COVID-19 pandemic has changed the landscape for immune therapies, including the use of monoclonal antibodies to protect vulnerable patients who can’t respond adequately to vaccination alone,” said Iskra Reic, AstraZeneca’s executive vice president for vaccines and immune therapies.
ICER Says No to Molnupiravir, Yes to Paxlovid and Fluvoxamine for Outpatient COVID Treatment
Merck’s oral COVID treatment molnupiravir lacks adequate evidence to support claims that it’s any more effective than symptomatic care.
South Africa Manufacturer Plans to Stop Making COVID-19 Vaccines
The plant has produced more than 200 million doses of COVID-19 vaccines.
NIH Shares COVID-19 Technologies With Medicines Patent Pool
The technologies are also made available through the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) program.
FDA Encourages Veru to Submit EUA Application for COVID-19 Therapy
In the wake of strongly positive data and an FDA go-ahead, Veru will seek an Emergency Use Authorization (EUA) for sabizabulin, its investigational COVID-19 therapy.
Moderna Completes EUA Submission for Use of COVID-19 Vaccine in Children
Spikevax is not currently authorized or approved for children under 18.
Emergent Hid Quality Problems With COVID-19 Vaccines, New Report Shows
The troubled manufacturing plant Emergent BioSolutions concealed proof of quality problems at its Baltimore, Md., location just a month and a half before it told the FDA that 15 million COVID-19 vaccine doses manufactured there had been contaminated.
FDA Provides Update on Mesa Biotech’s Recall of Its Accula COVID-19 Tests
False positive results could lead to further exposure of uninfected individuals to the SARS-CoV-2 virus, the agency said.
UK Study Shows Promising Data for Fourth COVID-19 Vaccine Shot
The UK currently permits people over age 75 and people who are immunosuppressed to get the fourth COVID-19 vaccine shot.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.